TargetMol

ARRY-403 (AMG-151)

Product Code:
 
TAR-T30142
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30142-1mg1mg£864.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30142-5mg5mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30142-10mg10mg£2,215.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30142-25mg25mg£3,251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30142-50mg50mg£4,352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30142-100mg100mg£5,846.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ARRY-403 (AMG-151) is an oral allosteric glucokinase (GK) activator for the treatment of type 2 diabetes mellitus (T2DM).
CAS:
1304015-76-6
Formula:
C20H18N6O3S2
Molecular Weight:
454.52
Pathway:
Metabolism
Purity:
0.98
SMILES:
Cc1ncccc1Oc1cc(Sc2ccccn2)cnc1Nc1nc(ns1)[C@H](O)CO
Target:
Glucokinase

References

1. Katz L, Manamley N, Snyder WJ, Dodds M, Agafonova N, Sierra-Johnson J, Cruz M, Kaur P, Mudaliar S, Raskin P, Kewalramani R, Pellacani A. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes Obes Metab. 2016 Feb;18(2):191-5. doi: 10.1111/dom.12586. Epub 2015 Dec 14. PubMed PMID: 26434934. 2. Chung J, Alvarez-Nunez F, Chow V, Daurio D, Davis J, Dodds M, Emery M, Litwiler K, Paccaly A, Peng J, Rock B, Wienkers L, Yang C, Yu Z, Wahlstrom J. Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility. J Pharm Sci. 2015 Apr;104(4):1522-32. doi: 10.1002/jps.24339. Epub 2015 Jan 15. PubMed PMID: 25641187.